Claude Maraoui - Nov 16, 2021 Form 3/A - Amendment Insider Report for Journey Medical Corp (DERM)

Role: President & CEO, Director
Signature: /s/ Claude Maraoui
Stock symbol: DERM
Transactions as of: Nov 16, 2021
Transactions value $: $0
Form type: 3/A - Amendment
Date filed: 4/4/2022, 04:39 PM
Date Of Original Report: Nov 26, 2021
Next filing: Jul 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DERM	COMMON STOCK						1.89M	Nov 16, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Form 3 amendment is being filed to correct the original Form 3 originally filed on November 26, 2021, which (i) incorrectly stated the number of restricted stock units granted to Mr. Maraoui and total number of shares of Journey Medical Corporation's common stock owned by Mr. Maraoui and (ii) omitted the vesting schedule of his restricted stock units discussed below.
F2	Includes 442,530 unvested Restricted Stock Units granted to Mr. Maraoui, which will vest in accordance with the following schedule: 147,362 shares on the fifteenth day of the eighteenth month following the closing of our initial public offering (the "Tranche 1 Vesting Date"); 147,362 of which will vest nine months after the Tranche 1 Vesting Date (the "Tranche 2 Vesting Date"), and 147,806 of which will vest nine months after the Tranche 2 Vesting Date.

Content

This Form 3 amendment is being filed to correct the original Form 3 originally filed on November 26, 2021, which (i) incorrectly stated the number of restricted stock units granted to Mr. Maraoui and total number of shares of Journey Medical Corporation's common stock owned by Mr. Maraoui and (ii) omitted the vesting schedule of his restricted stock units discussed below.

Includes 442,530 unvested Restricted Stock Units granted to Mr. Maraoui, which will vest in accordance with the following schedule: 147,362 shares on the fifteenth day of the eighteenth month following the closing of our initial public offering (the "Tranche 1 Vesting Date"); 147,362 of which will vest nine months after the Tranche 1 Vesting Date (the "Tranche 2 Vesting Date"), and 147,806 of which will vest nine months after the Tranche 2 Vesting Date.